Trial results

46:37it's it's way lower you you're you're you've you've been able to do enough pre-work here where the the the patient risk profile is also lower and it's so fascinating because we've been studying the heart >> vigorously for a very very long time now and so we have a lot of knowledge >> as it relates to this particular organ >> and it builds This is built on all of that knowledge out of thin air, right? And I think that's a really important point here, which is like we can do things like this now because we've spent so much time. >> Yeah. >> Gathering data about the heart, building simulations around the heart and then so you can now go to an individual patient

47:18and then apply all of that that history of knowledge, create a personalized solution to them and and basically run the surgery in in what uh in in uh in silica. Yeah, exactly. Uh ver before you go >> invivo. Invivo. [laughter] >> Yes, that's exactly right. >> That's incredible. >> Yeah. And in in a 10patient trial, so this was all FDA approved, by the way. Um the the trial was FDA approved. And in the 10 patient trial, all participants were free of the sustained arhythmias at the follow-up. >> Incredible. >> And that's far exceeding the typical rate, which is like 60% success rate, right? So for 10 people to have success like at 60% that's 6 to the 10th power

48:01which is point about 06. So like that happening by chance among like a normal w with normal procedures is like um less than 1%. But here it was happening right >> 100% of the time. Yeah. Every time. >> Exactly. [laughter] So here you don't even Yeah. This isn't you can't really argue on it. The other thing that was crazy is that um eight of the patients were entirely off anti-arithmia medications. They didn't even have to take medications. >> That's two of them had lower doses, but eight of them were just like done. >> We're good. >> Yeah, >> they did it. And I I you know, I think one of the things technology understandably is very complicated in our modern era in consumer applications

48:43and a variety of other contexts and the economics that relates to people who make technological discoveries. But the biomeds is hugely patient outcomes. >> The health system is not what we're talking about when we talk about just the the raw ability to get the solution. And then we have to deal with how do we make this more accessible and there's sort of the public health healthcare insurance paradigm that's needs to be dealt with. But our ability to have real solutions to these problems that are this effective is is so again you know

49:26I'm sure many people who are listening us personally others have had friends family who have had maybe not this specific heart related issue but adjacent related heart related issues and it's the number one killer of people in the US >> um and we're slowly chipping away at the tool set to start to solve these problems. Again, I and it's it's